KGF improves overall survival and tumor burden of tumor-bearing mice undergoing allogeneic BMT and tumor vaccination. B6 mice were inoculated intravenously with syngeneic B16 melanoma (5 × 104 cells) 7 days before T cell–depleted BMT. BMT alone had a significant effect on overall survival (A, *P < .001). Mice were treated with KGF as described in Figure 1, and some mice were vaccinated every 5 days starting on day 14 with VP22-opt-TRP1 plasmid DNA. Mice were followed daily for survival and were euthanized when experiencing respiratory distress or found to have progressive large bulky tumors greater than 1 cm in diameter. Data shown are pooled from 4 experiments with similar results (B, *P = .003, **P = .01, KGF + BMT vs KGF + BMT + DNA not significant, P = .08). In a similar experiment, B16-TGL (105 cells) expressing firefly luciferase was substituted for B16. Weekly, starting day 21 after tumor challenge, mice were evaluated with in vivo bioluminescence imaging, with median values of luminescence shown in panel C, pooled from 2 experiments with similar results. Individual data from day 35 are shown in panel D (*P = .047, **P = .008).
